An Open-Label Extension Study to Investigate the Long-Term Safety and Tolerability of THC/CBD Oromucosal Spray and Oromucosal THC Spray in Patients With Terminal Cancer-Related Pain Refractory to Strong Opioid Analgesics Jeremy R. Johnson, BSc, MB ChB, FRCP, Dominique Lossignol, MB ChB, MRCG, DRCOG, Mary Burnell-Nugent, MB BChir, Marie T. Fallon, MB ChB, MD, FRCP (E), FRCP (Glasg) Journal of Pain and Symptom Management Volume 46, Issue 2, Pages 207-218 (August 2013) DOI: 10.1016/j.jpainsymman.2012.07.014 Copyright © 2013 U.S. Cancer Pain Relief Committee Terms and Conditions
Fig. 1 Breakdown of patients enrolled in the study. RCT=randomized controlled trial; SAE=serious adverse event; THC=Δ9-tetrahydrocannabinol; CBD=cannabidiol; ITT=intention to treat. Journal of Pain and Symptom Management 2013 46, 207-218DOI: (10.1016/j.jpainsymman.2012.07.014) Copyright © 2013 U.S. Cancer Pain Relief Committee Terms and Conditions
Fig. 2 Mean Brief Pain Inventory Short-Form (BPI-SF) scores for pain severity, average pain, worst pain, and pain interference domains. Journal of Pain and Symptom Management 2013 46, 207-218DOI: (10.1016/j.jpainsymman.2012.07.014) Copyright © 2013 U.S. Cancer Pain Relief Committee Terms and Conditions
Fig. 3 Mean European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) scores for functional status domains. Journal of Pain and Symptom Management 2013 46, 207-218DOI: (10.1016/j.jpainsymman.2012.07.014) Copyright © 2013 U.S. Cancer Pain Relief Committee Terms and Conditions
Fig. 4 Mean European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) scores for adverse symptom domains. Journal of Pain and Symptom Management 2013 46, 207-218DOI: (10.1016/j.jpainsymman.2012.07.014) Copyright © 2013 U.S. Cancer Pain Relief Committee Terms and Conditions